Insight

Talha Badar: Clinical outcome of AYA with Ph+ve ALL

Photo from Talha Badar/X

Jun 18, 2024, 22:49

Talha Badar: Clinical outcome of AYA with Ph+ve ALL

Talha Badar shared on X: .

“Clinical outcome of adolescents and young adults (AYA) with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ve ALL).

Additional cytogenetic abnormalities are similar in both age groups.

Comparable proportions of patients received intensive chemotherapy (IC) plus tyrosine kinase inhibitors (TKI) and allo-HCT in AYA and non-AYA.”

Source: Talha Badar/X

Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.

Adam DuVall adolescents and young adults Alexander Coltoff allo-HCT Anand Patel AYA cancer cytogenetic abnormalities Emily Curran intensive chemotherapy (IC) Mayo Clinic non-AYA OncoDaily Oncology Ph+ve ALL Philadelphia chromosome-positive acute lymphoblastic leukemia Rory M. Shallis tyrosine kinase inhibitors (TKI) Vamsi Kota

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity